This study's findings will help congenital neurological disease (e.g. spinal muscular atrophy) specialists better understand the mechanisms and components involved in CNS development. Notably, the findings of this work demonstrate unequivocally that Ddx20 is a novel Olig2-interacting factor and a potent suppressor of the p53 pathway, contributing to the maintenance of neuronal and oligodendrocyte progenitor cells during CNS development. Therefore, Ddx20 and Olig2 are promising molecular targets for development of future therapeutic strategies.
